Pfiz­er gets biosim­i­lar ap­proved for Hu­mi­ra, set­ting up com­pe­ti­tion — in 2023

In the sto­ry law­mak­ers and drug pric­ing re­form ad­vo­cates have told about the drug in­dus­try, there are per­haps few greater vil­lains than Hu­mi­ra and its mak­er Ab­b­Vie.

Be­tween 2012 and 2018, Ab­b­Vie upped the drug’s an­nu­al af­ter-re­bates cost from $19,000 to $38,000 in the US, with stick­er prices now over $60,000 per year — in­creas­es that led to ac­cu­sa­tions of price goug­ing, most re­cent­ly from De­mo­c­ra­t­ic pres­i­den­tial fron­trun­ner Eliz­a­beth War­ren.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.